Compare · NXL vs TMDX
NXL vs TMDX
Side-by-side comparison of Nexalin Technology Inc. (NXL) and TransMedics Group Inc. (TMDX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NXL and TMDX operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- TMDX is the larger of the two at $2.65B, about 1032.9x NXL ($2.6M).
- Over the past year, NXL is down 94.5% and TMDX is down 39.8% - TMDX leads by 54.7 points.
- NXL has been more active in the news (9 items in the past 4 weeks vs 2 for TMDX).
- TMDX has more recent analyst coverage (20 ratings vs 0 for NXL).
- Company
- Nexalin Technology Inc.
- TransMedics Group Inc.
- Price
- -
- -
- Market cap
- $2.6M
- $2.65B
- 1M return
- -50.88%
- -18.36%
- 1Y return
- -94.51%
- -39.77%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2022
- 2019
- News (4w)
- 9
- 2
- Recent ratings
- 0
- 20
TransMedics Group Inc.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains the organ at a near-physiologic state allowing physicians to assess and improve the condition of lungs between the donor and recipient sites; OCS Heart, a portable, warm perfusion, and monitoring system designed to keep a donor heart at a human-like, metabolically active state; and OCS Liver, a system that is evaluated in clinical trials for utilized and unutilized donor livers. TransMedics Group, Inc. was founded in 1998 and is headquartered in Andover, Massachusetts.
Latest NXL
- SEC Form EFFECT filed by Nexalin Technology Inc.
- Amendment: SEC Form S-1/A filed by Nexalin Technology Inc.
- Nexalin Technology Regains Compliance with Nasdaq Minimum Bid Price Requirement; Nasdaq Hearings Panel Grants Request for Continued Listing
- Nexalin Technology Inc. filed SEC Form 8-K: Other Events
- Nexalin Technology Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
- These Stocks Roar into October with Fresh Catalysts
- Nexalin Technology Signs Definitive Exclusive Distribution and Local Manufacturing Agreement for Brazil and South America, Marking a Major Step in its Transition Toward Commercial Revenue Generation
- Nexalin Technology Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- SEC Form S-8 filed by Nexalin Technology Inc.
- SEC Form S-1 filed by Nexalin Technology Inc.
Latest TMDX
- Barclays initiated coverage on TransMedics Group with a new price target
- SEC Form 3 filed by new insider Araujo Fernando N.
- Director Weill David bought $109,058 worth of shares (1,336 units at $81.63), increasing direct ownership by 9% to 16,392 units (SEC Form 4)
- TransMedics Group Inc. filed SEC Form 8-K: Regulation FD Disclosure
- TransMedics Appoints Fernando Araujo as Chief Financial Officer and Reiterates 2026 Financial Outlook
- TransMedics to Present at Upcoming September Investor Conferences
- Director Tobin James R gifted 18,000 shares (SEC Form 4)
- SEC Form 10-Q filed by TransMedics Group Inc.
- TransMedics Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- TransMedics Reports Second Quarter 2026 Financial Results